Dietary betaine supplementation increases Fgf21 levels to improve glucose homeostasis and reduce hepatic lipid accumulation in mice

Diabetes

Volumn 65, Issue 4, 2016, Pages 902-912

  Ejaz, Asma ^a   Martinez Guino, Laura ^b   Goldfine, Allison B ^a   Ribas Aulinas, Francesc ^c   De Nigris, Valeria ^d   Ribó, Sílvia ^b   Gonzalez Franquesa, Alba ^d   Garcia Roves, Pablo M ^c,d,e   Li, Elizabeth ^a   Dreyfuss, Jonathan M ^a,f   Gall, Walt ^g   Kim, Jason K ^h   Bottiglieri, Teodoro ⁱ   Villarroya, Francesc ^c   Gerszten, Robert E ^j   Patti, Mary Elizabeth ^a   Lerin, Carles ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HOSPITAL SANT JOAN DE DÉU   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

^d INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^e INSTITUTO DE SALUD CARLOS III   (Spain)

^f Boston University   (United States)

^g METABOLON INC   (United States)

^h UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

ⁱ BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^j MASSACHUSETTS GENERAL HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BETAINE; FIBROBLAST GROWTH FACTOR 21; FIBROBLAST GROWTH FACTOR; GLUCOSE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DIET INDUCED OBESITY; DIET SUPPLEMENTATION; ENERGY EXPENDITURE; FAT CONTENT; FEMALE; FGF21 GENE; GENE; GLUCOSE HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID LIVER LEVEL; LIPID STORAGE; MALE; METABOLOME; NONHUMAN; PLASMA; PRIORITY JOURNAL; RAT; ANIMAL; BLOOD; C57BL MOUSE; CELL CULTURE; CHEMICALLY INDUCED; DIETARY SUPPLEMENT; DRUG EFFECTS; FATTY LIVER; GENETICS; GLUCOSE INTOLERANCE; HOMEOSTASIS; KNOCKOUT MOUSE; LIPID METABOLISM; LIVER; METABOLISM; MOUSE;

ADULT; ANIMALS; BETAINE; CELLS, CULTURED; DIETARY SUPPLEMENTS; FATTY LIVER; FEMALE; FIBROBLAST GROWTH FACTORS; GLUCOSE; GLUCOSE INTOLERANCE; HOMEOSTASIS; HUMANS; LIPID METABOLISM; LIVER; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT;

EID: 84962135673     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db15-1094     Document Type: Article

References (56)

1. Martin BC, Warram JH, Krolewski A.S., Bergman RN, Soeldner JS, Kahn CR. Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study. Lancet 1992; 340:925-929
2. Knowler WC, Barrett-Connor E, Fowler S.E., et al.; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346:393-403
3. Gall WE, Beebe K, Lawton K.A., et al.; RISC Study Group. alpha-hydroxybutyrate is an early biomarker of insulin resistance and glucose intolerance in a nondiabetic population. PLoS One 2010; 5:e10883
4. Newgard CB, An J, Bain J.R., et al. A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab 2009; 9:311-326
5. Wang TJ, Larson MG, Vasan R.S., et al. Metabolite profiles and the risk of developing diabetes. Nat Med 2011; 17:448-453
6. Walford GA, Ma Y, Clish C., et al. Metabolite profiles of diabetes incidence and intervention response in the Diabetes Prevention Program. Diabetes. 9 February 2016 [Epub ahead of print]. DOI:10.2337/db15-1063
7. Craig SA. Betaine in human nutrition. Am J Clin Nutr 2004; 80:539-549
8. Detopoulou P, Panagiotakos DB, Antonopoulou S, Pitsavos C., Stefanadis C. Dietary choline and betaine intakes in relation to concentrations of inflammatory markers in healthy adults: the ATTICA study. Am J Clin Nutr 2008; 87:424-430
9. Konstantinova SV, Tell GS, Vollset S.E., Nygård O, Bleie Ø, Ueland PM. Divergent associations of plasma choline and betaine with components of metabolic syndrome in middle age and elderly men and women. J Nutr 2008; 138:914-920
10. Mato JM, Martínez-Chantar ML, Lu SC. Methionine metabolism and liver disease. Annu Rev Nutr 2008; 28:273-293
11. Schwab U, Törrönen A, Meririnne E, et al. Orally administered betaine has an acute and dose-dependent effect on serum betaine and plasma homocysteine concentrations in healthy humans. J Nutr 2006; 136:34-38
12. Graham IM, Daly LE, Refsum H.M., et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA 1997; 277:1775-1781
13. Song Z, Deaciuc I, Zhou Z., et al. Involvement of AMP-activated protein kinase in beneficial effects of betaine on high-sucrose diet-induced hepatic steatosis. Am J Physiol Gastrointest Liver Physiol 2007; 293:G894-G902
14. Kharbanda KK, Mailliard ME, Baldwin C.R., Beckenhauer HC, Sorrell MF, Tuma DJ. Betaine attenuates alcoholic steatosis by restoring phosphatidylcholine generation via the phosphatidylethanolamine methyltransferase pathway. J Hepatol 2007; 46:314-321
15. Kathirvel E, Morgan K, Nandgiri G., et al. Betaine improves nonalcoholic fatty liver and associated hepatic insulin resistance: a potential mechanism for hepatoprotection by betaine. Am J Physiol Gastrointest Liver Physiol 2010; 299: G1068-G1077
16. Wang Z, Yao T, Pini M., Zhou Z, Fantuzzi G, Song Z. Betaine improved adipose tissue function in mice fed a high-fat diet: a mechanism for hepatoprotective effect of betaine in nonalcoholic fatty liver disease. Am J Physiol Gastrointest Liver Physiol 2010; 298:G634-G642
17. Jin W, Goldfine AB, Boes T, et al Increased SRF transcriptional activity in human and mouse skeletal muscle is a signature of insulin resistance. J Clin Invest 2011; 121:918-929
18. Planavila A, Redondo I, Hondares E., et al. Fibroblast growth factor 21 protects against cardiac hypertrophy in mice. Nat Commun 2013; 4:2019
19. Roberts LD, Souza AL, Gerszten R.E., Clish CB. Targeted metabolomics. Current Protocols in Molecular Biology 2012; 98:30.2:30.2.1-30.2.24
20. Pfalzer AC, Choi S-W, Tammen SA, et al S-adenosylmethionine mediates inhibition of inflammatory response and changes in DNA methylation in human macrophages. Physiol Genomics 2014; 46:617-623
21. Gnaiger E. Capacity of oxidative phosphorylation in human skeletal muscle: new perspectives of mitochondrial physiology. Int J Biochem Cell Biol 2009; 41: 1837-1845
22. Bergman RN, Prager R, Volund A., Olefsky JM. Equivalence of the insulin sensitivity index in man derived by the minimal model method and the euglycemic glucose clamp. J Clin Invest 1987; 79:790-800
23. Alirezaei M, Khoshdel Z, Dezfoulian O., Rashidipour M, Taghadosi V. Beneficial antioxidant properties of betaine against oxidative stress mediated by levodopa/benserazide in the brain of rats. J Physiol Sci 2015; 65:243-252
24. Jung YS, Kim SJ, Kwon Y, et al Alleviation of alcoholic liver injury by betaine involves an enhancement of antioxidant defense via regulation of sulfur amino acid metabolism. Food Chem Toxicol 2013; 62:292-298
25. Adams AC, Yang C, Coskun T., et al. The breadth of FGF21's metabolic actions are governed by FGFR1 in adipose tissue. Mol Metab 2012; 2:31-37
26. Ding X, Boney-Montoya J, Owen B.M., et al. βKlotho is required for fibroblast growth factor 21 effects on growth and metabolism. Cell Metab 2012; 16:387-393
27. Véniant M.M., Hale C, Helmering J., et al. FGF21 promotes metabolic homeostasis via white adipose and leptin in mice. PLoS One 2012; 7:e40164
28. Fisher FM, Kleiner S, Douris N., et al. FGF21 regulates PGC-1α and browning of white adipose tissues in adaptive thermogenesis. Genes Dev 2012; 26:271-281
29. Cheng S, Rhee EP, Larson M.G., et al. Metabolite profiling identifies pathways associated with metabolic risk in humans. Circulation 2012; 125:2222-2231
30. Magnusson M, Wang TJ, Clish C, et al Dimethylglycine deficiency and the development of diabetes. Diabetes 2015; 64:3010-3016
31. Konstantinova SV, Tell GS, Vollset S.E., Ulvik A., Drevon CA, Ueland PM. Dietary patterns, food groups, and nutrients as predictors of plasma choline and betaine in middle-aged and elderly men and women. Am J Clin Nutr 2008; 88: 1663-1669
32. Tang WHW, Wang Z, Levison B.S., et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med 2013; 368:1575-1584
33. Wang Z, Tang WHW, Buffa JA, et al Prognostic value of choline and betaine depends on intestinal microbiota-generated metabolite trimethylamine-N-oxide. Eur Heart J 2014; 35:904-910
34. Ball CR. Actions of betaine, carnitine and choline on the pattern of hepatic liposis in mice fed a high-fat, low-protein diet. Anat Rec 1964; 149:677-689
35. Dahlhoff C, Worsch S, Sailer M., et al. Methyl-donor supplementation in obese mice prevents the progression of NAFLD, activates AMPK and decreases acyl-carnitine levels. Mol Metab 2014; 3:565-580
36. Kliewer SA, Mangelsdorf DJ Fibroblast growth factor 21: from pharmacology to physiology. Am J Clin Nutr 2010; 91:254S-257S
37. Gaich G, Chien JY, Fu H, et al The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metab 2013; 18:333-340
38. Inagaki T, Dutchak P, Zhao G., et al. Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab 2007; 5:415-425
39. Laeger T, Henagan TM, Albarado D.C., et al. FGF21 is an endocrine signal of protein restriction. J Clin Invest 2014; 124:3913-3922
40. Markan KR, Naber MC, Ameka M.K., et al. Circulating FGF21 is liver derived and enhances glucose uptake during refeeding and overfeeding. Diabetes 2014; 63:4057-4063
41. Badman MK, Pissios P, Kennedy A.R., Koukos G., Flier JS, Maratos-Flier E. Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab 2007; 5:426-437
42. Dushay J, Chui PC, Gopalakrishnan G.S., et al. Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology 2010; 139:456-463
43. Xu J, Lloyd DJ, Hale C, et al Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in dietinduced obese mice. Diabetes 2009; 58:250-259
44. Emanuelli B, Vienberg SG, Smyth G, et al Interplay between FGF21 and insulin action in the liver regulates metabolism. J Clin Invest 2014; 124:515-527
45. Coskun T, Bina HA, Schneider M.A., et al. Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 2008; 149:6018-6027
46. Ong KL, Rye K-A, O'Connell R, et al.; FIELD study investigators. Long-term fenofibrate therapy increases fibroblast growth factor 21 and retinol-binding protein 4 in subjects with type 2 diabetes. J Clin Endocrinol Metab 2012; 97:4701-4708
47. Chang MR, He Y, Khan T.M., et al. Antiobesity effect of a small molecule repressor of RORg. Mol Pharmacol 2015; 88:48-56
48. Véniant M.M., Sivits G, Helmering J., et al. Pharmacologic effects of FGF21 are independent of the "browning" of white adipose tissue. Cell Metab 2015; 21:731-738
49. Samms RJ, Smith DP, Cheng C.C., et al. Discrete aspects of FGF21 in vivo pharmacology do not require UCP1. Cell Reports 2015; 11:991-999
50. Chau MDL, Gao J, Yang Q., Wu Z, Gromada J. Fibroblast growth factor 21 regulates energy metabolism by activating the AMPK-SIRT1-PGC-1a pathway. Proc Natl Acad Sci U S A 2010; 107:12553-12558
51. Seale P, Conroe HM, Estall J, et al Prdm16 determines the thermogenic program of subcutaneous white adipose tissue in mice. J Clin Invest 2011; 121: 96-105
52. Deminice R, da Silva RP, Lamarre SG, et al. Betaine supplementation prevents fatty liver induced by a high-fat diet: effects on one-carbon metabolism. Amino Acids 2015; 47:839-846
53. Teng YW, Ellis JM, Coleman R.A., Zeisel SH. Mouse betaine-homocysteine S-methyltransferase deficiency reduces body fat via increasing energy expenditure and impairing lipid synthesis and enhancing glucose oxidation in white adipose tissue. J Biol Chem 2012; 287:16187-16198
54. Xu L, Huang D, Hu Q., Wu J, Wang Y, Feng J. Betaine alleviates hepatic lipid accumulation via enhancing hepatic lipid export and fatty acid oxidation in rats fed with a high-fat diet. Br J Nutr 2015; 113:1835-1843
55. Abdelmalek MF, Sanderson SO, Angulo P, et al Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial. Hepatology 2009; 50:1818-1826
56. Schwab U, Törrönen A, Toppinen L, et al. Betaine supplementation decreases plasma homocysteine concentrations but does not affect body weight, body composition, or resting energy expenditure in human subjects. Am J Clin Nutr 2002; 76:961-967